Strategic partnerships Braingaze has recent collaboration activity including a licensing agreement with Tris Pharma and a noted participation in PepsiCo’s Greenhouse Accelerator program, indicating openness to B2B partnerships and co-development opportunities that could be extended to pharmaceutical, medical device, and consumer health collaborations.

Clinical readiness With a track record of use in leading clinics and a focus on detecting, diagnosing, and treating cognitive disorders through eye movement as a biomarker, Braingaze presents a credible entry point for hospital systems, clinics, and specialty centers seeking digital therapeutics and diagnostic solutions.

Global IP leverage The patented concept of eye movement cognitive vergence provides a defensible differentiator and potential licensing or co-development angles for larger medtech players seeking unique cognitive assessment tools, enabling scaled deployment through partners.

Tech-enabled scale A tech stack spanning cloud services, AI, and modern web/mobile platforms suggests feasibility for enterprise integrations, data pipelines, and remote monitoring solutions, offering upsell opportunities around data analytics, telehealth workflows, and compliant digital health deployments.

Funding runway Current revenue under 1M with total funding around 1.6M indicates a lean growth stage ideal for strategic customers who can help accelerate product validation, co-development pilots, and joint go-to-market initiatives to reach larger healthcare networks.